Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia

Abstract

To investigate the lipoprotein effect of fenofibrate in hypercholesterolemia or combined hyperlipidemia (types II A and II B hyperlipidemias, respectively), 240 patients were recruited and 227 randomized to a double-blind randomized trial lasting 24 weeks and 192 patients continued to participate in an open-label phase for another 24 weeks. A 100-mg dose of fenofibrate or a matching placebo was given three times daily. Fenofibrate side effects in excess of placebo affected 6 percent of fenofibrate users and were confined almost entirely to skin rashes. In 180 hypercholesterolemic patients randomly assigned to receive fenofibrate versus placebo, triglyceride and very low-density lipoprotein cholesterol levels decreased 38 percent, total cholesterol levels decreased 17.5 percent, and low-density lipoprotein cholesterol levels decreased 20.3 percent with fenofibrate treatment. High-density lipoprotein cholesterol levels increased 11.1 percent with a decrease in the low-density lipoprotein cholesterol: high-density lipoprotein cholesterol ratio of 27 percent. All differences were statistically significant (p less than 0.01). In combined hyperlipidemic (type II B) patients, triglyceride levels decreased by 45 percent, very low-density lipoprotein cholesterol levels decreased 52.7 percent, total cholesterol levels decreased 16 percent, low-density lipoprotein cholesterol levels decreased 6 percent, and high-density lipoprotein levels increased 15.3 percent for a low-density lipopro…

Overview

Integrity signals

Registry

Crossref · 10.1016/0002-9343(87)90871-0

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Research works printed but not linked: 8

  1. Baker, 1982, Evaluation a long terme de l'activite hypolipidemiante et de la tolerance du fenofibrate, Prog Med, 110, 18
  2. Wulfert, 1982, Efficacy and tolerance of fenofibrate: a review of clinical experience, 87, 91
  3. Drouin, 1979, The effect of fenofibrate (procetofen) on the lipoprotein profile in patients affected by primary type II hyperlipoproteinemia, Curr Ther Res, 26, 350
  4. Lehtonen, 1981, Effet of procetofen on serum total cholesterol, triglyceride, and high density lipoprotein cholesterol concentrations in hyperlipoproteinemia, Int J Clin Pharmacol Ther Toxicol, 19, 534
  5. Michell, 1979, Treatment of hyperlipoproteinemia (HLP) type IIa with a new phenoxyisobuturic acid derivative, procetofen, Int J Clin Pharmacol Biopharm, 17, 503
  6. Vega G, Grundy SM: Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. JAMA 253; 2398-2403. · doi:10.1001/jama.1985.03350400082026
  7. Schwartzkopff, 1982, Untersuchungen zur Wirksamkeit von Bezafibrat und Fenofibrat auf erhehte Lipide des Blutes beim HLP Type IIa, IIb, und IV, Med Welt, 33, 631
  8. Bissonette, 1983, Use of gemfibrozil in patients with dyslipidemia: a double-blind comparison with placebo, Int Med for the Spec, 9, 132

Cited by

See all 65

Metadata

Authors
Knopp, R. H., Brown, W. V., Dujovne, C. A., Farquhar, J. W., Feldman, E. B., Goldberg, A. C., Grundy, S. M., Lasser, N. L., Mellies, M. J., Palmer, R. H., Samuel, P., Schonfeld, G., & Superko, H. R.
Affiliations
University of Washington (US)
Corresponding author
Knopp, Robert H.
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
1987-11
Volume
83
Issue
5
Pages
50-59
ISSN
0002-9343 (ISSN-L)
OpenAlex
W2106189850
Cited by
65
References
21
Citations by year
2023: 2 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 5 · 2012: 2
FWCI
8.77
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (3p30am030865-04s1, 1p30am035816-01)
  • National Heart, Lung, and Blood Institute (HL3-0086)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
hypercholesterolemia, mixed dyslipidemia, type II hyperlipidemia, serum lipoproteins, triglycerides, VLDL cholesterol, LDL cholesterol, HDL cholesterol, fibrates, drug tolerability, hypertriglyceridemia
MeSH terms
Adult, Aged, Clinical Trials as Topic, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type II, Hyperlipidemias, Lipoproteins, Male, Middle Aged, Fenofibrate, Propionates, Random Allocation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. https://app.cochat.ai/papers/10.1016/0002-9343(87)90871-0
The paper
Knopp, R. H., Brown, W. V., Dujovne, C. A., Farquhar, J. W., Feldman, E. B., Goldberg, A. C., Grundy, S. M., Lasser, N. L., Mellies, M. J., Palmer, R. H., Samuel, P., Schonfeld, G., & Superko, H. R. (1987). Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. The American Journal of Medicine. https://doi.org/10.1016/0002-9343(87)90871-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.